Category Archives: 2023

Scientific publication update: ASH meeting abstract 2023 (Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study)

Posted on December 15, 2023 by steve@pepromenebio.com

Irvine, CA, December 15, 2023 – An oral and poster abstract, “Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study”, has been published at American Society of Hematology Meeting 2023.   … Continue reading →

Posted in 2023 | Leave a comment

PeproMene Bio, Inc. Announced Completion of the First Dose Cohort and Opening of the Second Dose Cohort in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells)

Posted on September 13, 2023 by steve@pepromenebio.com

IRVINE, Calif., Sept. 11, 2023 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first dose cohort of its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) … Continue reading →

Posted in 2023 | Leave a comment